Double-Dose vaccine may protect HIV patients from hepatitis b
NCT ID NCT00670839
First seen Apr 13, 2026 · Last updated May 13, 2026 · Updated 6 times
Summary
This study tested whether a double-dose hepatitis B vaccine (40 micrograms) works better than the standard dose (20 micrograms) in people with HIV who had not responded to previous hepatitis B vaccines. The trial included 178 participants and measured how many developed protective antibodies one month after the final shot. The goal is to find a better way to protect HIV patients from severe liver disease caused by hepatitis B.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre de Soins de l'Infection par le VIH NHC, Hôpitaux Universitaires Strasbourg, 1 place de l'hôpital
Strasbourg, 67091 Cedex, France
Conditions
Explore the condition pages connected to this study.